ArticleCell reports2019
Modeling Human Cancer-induced Cachexia.
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 140 citations in OpenAlex.
- Neuromuscular junctions are stable in patients with cancer cachexia.The Journal of clinical investigation · 2020Trial
- A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.Nature medicine · 2026Article
- An iron-regulated methionine redox axis governs adipose browning and cancer cachexia.Nature cancer · 2026Article
- Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation.Cancers · 2026Review
- The Association Between Gut Microbiome and Cachexia in Colorectal Cancer: A Systematic Review.Cancers · 2026Review
- Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease.Molecular oncology · 2026Article
- Chemotherapy induces tissue NADbioRxiv : the preprint server for biology · 2026Article
- Impact of Hypertrophy-Oriented Resistance Training on Muscle Mass and Quality of Life in Patients with Unresectable Pancreatic Cancer (HY-PANC): Study Protocol for a Randomized Controlled Trial.Current protocols · 2026Article
- BMP4 derived from human gastrointestinal carcinoma cells impairs myogenic differentiation: A possibleInternational journal of oncology · 2026Article
- The Secretome of a Cachexia-Inducing Lung Tumor Impairs Mitochondrial Function and Skeletal Muscle Differentiation.Cancers · 2026Article
- Fiber-type vulnerability and proteostasis reprogramming in skeletal muscle during pancreatic cancer cachexia.JCI insight · 2026Article
- Pancreatic cancer-associated organ dysfunction promotes muscle autophagy and contributes to peripheral tissue wasting.bioRxiv : the preprint server for biology · 2026Article
- The effects of tissue inflammation on cancer cachexia.Biochimica et biophysica acta. Molecular basis of disease · 2026Review
- Patient-derived organoid xenografts model esophageal cancer cachexia and enable assessment of anti-inflammatory drug repositioning.iScience · 2026Article
- Silencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.Advanced healthcare materials · 2026Article
- Multi-omics profiling of cachexia-targeted tissues reveals a spatio-temporally coordinated response to cancer.Nature metabolism · 2026Article
- From complex algorithms to clinical practice: a multicenter machine learning model and simplified decision tree for predicting cachexia risk in gastric cancer.Frontiers in oncology · 2026Article
- Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer.Nature communications · 2025Article
- Review
- Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1.Nature communications · 2025Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
Cachexia is a wasting syndrome characterized by pronounced skeletal muscle loss. In cancer, cachexia is associated with increased morbidity and mortality and decreased treatment tolerance. Although advances have been made in understanding the mechanisms of cachexia, translating these advances to the clinic has been challenging. One reason for this shortcoming may be the current animal models, which fail to fully recapitulate the etiology of human cancer-induced tissue wasting. Because pancreatic ductal adenocarcinoma (PDA) presents with a high incidence of cachexia, we engineered a mouse model of PDA that we named KPP. KPP mice, similar to PDA patients, progressively lose skeletal and adipose mass as a consequence of their tumors. In addition, KPP muscles exhibit a similar gene ontology as cachectic patients. We envision that the KPP model will be a useful resource for advancing our mechanistic understanding and ability to treat cancer cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.